Ophidion

Executive Summary

Ophidion is an early-stage biopharmaceutical company based in San Diego, CA, advancing a proprietary carrier platform to deliver therapeutics across the blood-brain barrier (BBB) for neurodegenerative diseases. The platform is designed to enable noninvasive delivery of a range of agents, including gene-silencing molecules and biologics, addressing a critical unmet need in CNS drug development. Founded in 2018, the company aims to develop both disease-modifying and symptomatic therapies for conditions such as Alzheimer's, Parkinson's, and other serious CNS disorders. The technology has the potential to overcome a major hurdle in neurology—the BBB—and could unlock new treatment paradigms. As a private, early-stage entity, Ophidion has not disclosed significant funding or clinical milestones publicly. The company is likely in preclinical or discovery stages, focusing on lead optimization and initial proof-of-concept studies. Its success hinges on demonstrating the platform's safety and efficacy in animal models, securing partnerships or licensing deals, and eventually advancing to IND-enabling studies. Given the high-risk nature of CNS drug development and the company's limited public track record, near-term visibility is low. However, the platform's broad applicability and the urgent need for effective CNS therapies present a compelling long-term opportunity.

Upcoming Catalysts (preview)

• Q4 2026Completion of lead candidate preclinical proof-of-concept studies60% success
• Q1 2027Announcement of strategic partnership or licensing deal for platform50% success
• Q3 2027IND submission for lead program30% success